Literature DB >> 9056130

Gender differences in patients with schizophrenia and substance abuse.

M F Brunette1, R E Drake.   

Abstract

Co-occurring substance abuse is common among people with chronic mental illnesses such as schizophrenia. Although gender differences have been established among substance abusers in the general population and among people with schizophrenia, little is known about gender differences in people with the dual disorders of schizophrenia and substance abuse. This study examines gender differences in 37 women and 135 men with dual disorders, and finds many differences consistent with those found in people with single disorders: dually diagnosed women had more social contact and fewer legal problems but greater problems with victimization and medical illness compared with dually diagnosed men. Unexpectedly, men and women had similar courses and severities of substance abuse. These findings may be critical in planning effective services that explicitly address women's family and social needs, issues related to victimization, and high rates of medical illness.

Entities:  

Mesh:

Year:  1997        PMID: 9056130     DOI: 10.1016/s0010-440x(97)90090-0

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  16 in total

Review 1.  Managing comorbid schizophrenia and substance abuse.

Authors:  R E Drake; K T Mueser
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

Review 2.  Perpetration of violence, violent victimization, and severe mental illness: balancing public health concerns.

Authors:  Jeanne Y Choe; Linda A Teplin; Karen M Abram
Journal:  Psychiatr Serv       Date:  2008-02       Impact factor: 3.084

3.  Prevalence and correlates of criminal victimization among new admissions to outpatient mental health services in Hawaii.

Authors:  Annette S Crisanti; B Christopher Frueh; Olga Archambeau; John J Steffen; Nancy Wolff
Journal:  Community Ment Health J       Date:  2013-12-13

4.  A UK population-based study of the relationship between mental disorder and victimisation.

Authors:  Christina Hart; Renée de Vet; Paul Moran; Stephani L Hatch; Kimberlie Dean
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2011-12-28       Impact factor: 4.328

5.  The role of coercion in the treatment of women with co-occurring disorders and histories of abuse.

Authors:  Colleen Clark; Marion Becker; Julienne Giard; Ruta Mazelis; Andrea Savage; Wendy Vogel
Journal:  J Behav Health Serv Res       Date:  2005 Apr-Jun       Impact factor: 1.505

6.  Gender differences in substance use, consequences, motivation to change, and treatment seeking in people with serious mental illness.

Authors:  Amy Drapalski; Melanie Bennett; Alan Bellack
Journal:  Subst Use Misuse       Date:  2010-12-21       Impact factor: 2.164

7.  Trauma exposure and PTSD in women with schizophrenia and coexisting substance use disorders: comparisons to women with severe depression and substance use disorders.

Authors:  Jennifer M Aakre; Clayton H Brown; Kathleen M Benson; Amy L Drapalski; Jean S Gearon
Journal:  Psychiatry Res       Date:  2014-12-30       Impact factor: 3.222

8.  Predictors of initiation and engagement in substance abuse treatment among individuals with co-occurring serious mental illness and substance use disorders.

Authors:  Clayton H Brown; Melanie E Bennett; Lan Li; Alan S Bellack
Journal:  Addict Behav       Date:  2010-12-10       Impact factor: 3.913

9.  Gender differences in homeless persons with schizophrenia and substance abuse.

Authors:  M Brunette; R E Drake
Journal:  Community Ment Health J       Date:  1998-12

10.  Family intervention for co-occurring substance use and severe psychiatric disorders: participant characteristics and correlates of initial engagement and more extended exposure in a randomized controlled trial.

Authors:  Kim T Mueser; Shirley M Glynn; Corinne Cather; Roberto Zarate; Lindy Fox; James Feldman; Rosemarie Wolfe; Robin E Clark
Journal:  Addict Behav       Date:  2009-04-01       Impact factor: 3.913

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.